

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

STRATEGIC ALLIANCE AGREEMENT WITH KEYMED BIOSCIENCE (CHENGDU) CO., LTD

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**,” together with its subsidiaries, the “**Group**”) is pleased to announce that on 22 September 2021, Shanghai JMT-Bio Technology Co., Ltd.* (上海津曼特生物科技有限公司, “**JMT-Bio**”), a wholly-owned subsidiary of the Company, has entered into a strategic alliance agreement (the “**Agreement**”) with Keymed Bioscience (Chengdu) Co., Ltd. (康諾亞生物醫藥科技(成都)有限公司, “**Chengdu Keymed**”), a wholly-owned subsidiary of Keymed Biosciences Inc. (“**Keymed Bio**”).

Under the terms of the Agreement, JMT-Bio and Chengdu Keymed shall jointly identify, research, develop and commercialize one or more products for nervous system diseases (the “**Collaboration Products**”). JMT-Bio will primarily be responsible for clinical development and commercialization of the Collaboration Product(s) and Chengdu Keymed will primarily be responsible for pre-clinical research and development of the Collaboration Product(s).

The parties have agreed to establish a joint steering committee consisting of six members, with three members nominated by each of JMT-Bio and Chengdu Keymed, the joint steering committee shall discuss and determine, among other things, strategic and critical matters regarding the Collaboration Products.

The Company believes that the strategic alliance will further strengthen the collaboration between the Group and Keymed Bio, where both parties will further utilize their respective advantages, coordinate their resources to jointly promote the development of nervous system diseases related drugs.

Keymed Bio, a company listed on the Main Board of the Stock Exchange of Hong Kong Limited (Stock Code: 2162), is an innovative biotech company established in 2016, focusing on novel antibodies and other therapeutic proteins drugs. It was founded by a team of experts with rich experience in the transformation and industrialization of scientific and technological achievements in China and abroad with over 200 employees. It has established R&D centers and manufacture bases for clinical trials in Chengdu, Shanghai and Beijing.

This announcement is made by the Company on a voluntary basis to provide information to shareholders and potential investors of the Company. There is no assurance that any Collaboration Products will ultimately be successfully developed, marketed and/or commercialized by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
CSPC Pharmaceutical Group Limited
Cai Dongchen
Chairman

Hong Kong, 23 September 2021

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive Directors; Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan and Mr. LAW Cheuk Kin Stephen as independent non-executive Directors.

** For identification purposes only*